Nov 9, 2026 · 50 min
AbbVie builds a risk-managed neuroscience portfolio
Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
The episode shows why neuroscience success depends on coordinated decisions across biology, trials, delivery, patient value, and commercial readiness.
- 1AbbVie balances near-term neuroscience opportunities with higher-risk bets across psychiatry, pain, movement disorders, and neurodegeneration.
- 2Biomarkers, study execution, formulation, devices, and patient-centered evidence can matter as much as the underlying molecule.
- 3Psychedelic medicines and China partnerships offer growth opportunities, but regulatory, infrastructure, policy, and market risks remain substantial.
Don't miss
Kelley explains why psychedelic medicines may become a larger part of AbbVie’s psychiatry portfolio while stressing the infrastructure and regulatory hurdles ahead.
The brief
Sean Kelley, who leads neuroscience at AbbVie, frames portfolio strategy as a balancing act: preserve near-term opportunities while committing selectively to long-term platforms.
The central argument is that neuroscience programs fail for reasons beyond biology. Trial execution, biomarkers, formulation, delivery, and patient value can determine whether a promising asset advances.
AbbVie’s portfolio spans psychiatry, migraine and pain, movement disorders, neurodegeneration, neuroimmunology, and therapeutic toxins, combining acquisitions, partnerships, incremental gains, and transformative bets.
The psychedelic strategy illustrates the upside and the friction: bretecilizumab could expand psychiatry, but regulation, clinical capacity, infrastructure, and market readiness will shape adoption.
Kelley’s advice to biotech founders is practical: make the patient value proposition clear and bring evidence that reduces uncertainty across preclinical or clinical development.
What was said on this episode
12 statements · 10 positive · 1 negative · 1 neutral
- Sean Kelleyon Pharmaceutical platform investmentPositive2:34
Pharmaceutical companies should commit resources to promising platforms and seek leadership.
“we need to place thoughtful bets and invest to win in those particular areas”
Listen at 2:34
- Sean Kelleyon Pharmaceutical portfolio strategyPositive3:27
A long-term pharmaceutical strategy requires balancing short- and long-term portfolio risks.
“we need to create a balanced portfolio, balancing both short and long-term risks”
Listen at 3:27
- Sean Kelleyon Neuroscience clinical-trial executionNeutral8:05
Study execution is as important as the drug itself to neuroscience trial outcomes.
“the way we execute the studies is just as important as what the drug contributes”
Listen at 8:05
- Sean Kelleyon Psychiatry clinical developmentPositive8:31
Adaptive, disciplined execution materially affects psychiatry program outcomes.
“our ability to adapt, remain agile, but also execute with disciplined focus around psychiatry is really important to the outcome of our programs”
Listen at 8:31
- Sean Kelleyon BreticilizumabPositive29:45
Breticilizumab may bring many patients with depression to remission within two weeks.
“a very high portion of people after just 2 doses of breticilizumab get to remission, and that's as early as 2 weeks”
Listen at 29:45
- Sean Kelleyon BreticilisinPositive30:18
Breticilisin could enable remission within weeks, unlike standard depression treatment.
“they could be in remission and within a couple of weeks. So that's rewriting the textbook for the treatment of psychiatry.”
Listen at 30:18
- Sean Kelleyon BreticilisinPositive32:04
Breticilisin’s antidepressant response remained durable for up to 74 days in available data.
“that kind of response is a resilient response as well. So it's a durable response in the data we have up to 74 days.”
Listen at 32:04
- Sean Kelleyon Psychedelic therapy regulation in Japan and ChinaNegative37:06
Regulatory development requirements for psychedelic therapies remain uncertain in Japan and China.
“there's some uncertainty about what development will need to look like for Japan and China”
Listen at 37:06
- Sean Kelleyon Interventional psychiatry infrastructurePositive37:44
Building interventional psychiatry capacity is important for launching psychedelic treatments.
“some of the building up interventional psychiatry, preparing practices for the launch of something like reticulostatin will be important”
Listen at 37:44
- Sean Kelleyon Large pharmaceutical companies in psychedelic medicinePositive38:38
More large pharmaceutical companies will enter psychedelic medicine.
“you're going to see more large companies jump into the space”
Listen at 38:38
- Sean Kelleyon China neuroscience innovationPositive40:51
China is a meaningful source of neuroscience innovation.
“it's a meaningful source of innovation, uh, in China as well”
Listen at 40:51
- Sean Kelleyon Chinese clinical-trial sitesPositive42:39
Chinese sites can enroll AbbVie studies faster than sites in the US or Europe.
“they're able to enroll these studies very quickly. More so than we could do in US or Europe.”
Listen at 42:39
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.